Table 2.
Variation in VEGF and NRG-1β Levels by CAD Severity
| median (range) ± SD | No CAD | Mild CAD | Moderate CAD | Severe CAD | ||||
|---|---|---|---|---|---|---|---|---|
| Duke Score 0 | Duke Score 2 | Duke Score 4 – 6 | Duke Score 8 –12 | |||||
| n = 21 | n = 12 | n = 16 | n = 11 | |||||
| serum VEGF (pg/ml) | 176 (16 – 1538) | ± 491 | 260 (16 –813) | ± 294 | 200 (16 –822) | ± 263 | 122 (16 –496) | ± 209 |
| plasma VEGF (pg/ml) | 101 (16 –1399) | ± 293 | 80 (30 –257) | ± 728 | 237 (30 –744) | ± 215 | 256 (55 –370) | ± 120 |
| serum NRG (ng/ml) | 2.6 (0.2 –19.1) | ± 5.5 | 1.8 (0.2 –11.8) | ± 3.1 | 1.3 (0.2 –6.4) | ± 2.1 | 0.5 (0.2 –7.9) | ± 2.4 |
| plasma NRG (ng/ml) | 4.1 (2.0 –12.9) | ± 2.9 | 4.0 (2.9 – 7.8) | ± 1.5 | 3.4 (1.4 –6.0) | ± 1.3 | 3.0 (1.4 –7.2) | ± 1.5 |